Team | 199 Biotechnologies

Great minds, behind great things

Boris Djordjevic

CEO & Founder

Boris is the founder and CEO of 199 Biotechnologies and 199 Clinic, dedicated to translating research in partial reprogramming, gene therapies, and preventive and longevity medicine into clinical products; with a decade of entrepreneurial experience in health and wellness in China, he is now also working on AI and Machine Learning applications for biopharma in the UK.

Emad Moeendarbary

Chief Scientific Officer

Mechanical Engineer and Professor of Mechanobiology at University College London (UCL) and Principal Cancer Research UK Investigator, Emad has made significant strides in cell mechanics during his research at UCL, London Centre for Nanotechnology, University of Cambridge, and Massachusetts Institute of Technology. His research explores cellular mechanics in ageing, cell biomechanics in the central nervous system, and microfluidic technologies in cancer metastasis. He has a portfolio of publications on high-impact journals such as Nature Communications and Nature Materials.

Joao Pedro de Magalhaes

Scientific Advisor

Chair of Molecular Biogerontology at the University of Birmingham, leads the Genomics of Ageing and Rejuvenation Lab, focusing on genomic approaches to ageing; he holds a PhD from the University of Namur and completed a postdoc with Prof George Church at Harvard Medical School; with over 100 publications and numerous invited talks, his pioneering research in gene networks and long-lived species genomes aims to develop interventions to improve health and combat age-related diseases.

199 Biotechnologies is pioneering the future of longevity by developing innovative therapies that target the root causes of aging.

Mission

199 Biotechnologies aims to develop and deliver groundbreaking therapeutics for age-related diseases and reverse the cellular aspects of aging. By bridging the gap between academic research and clinical application, we bring innovative treatments to patients more swiftly and effectively. Our mission is to harness the potential of epigenetic reprogramming to fight disease, repair cellular damage, and restore function lost with age.

Vision

We envision a future where age-related diseases are effectively treated at their source, transforming healthcare and extending healthspan. We are committed to revolutionizing the treatment of aging by addressing its root causes, reducing the global burden of chronic diseases, and enhancing the quality of life for millions worldwide. Through bold, scientific innovation and a step-by-step approach, we aim to set new standards in longevity and healthspan.

Values

We are pioneers in longevity science, driven by innovation, excellence, integrity, and a sense of urgency. We develop safe, effective, and accessible therapies to extend healthspan and combat age-related diseases. Collaboration, adaptability, continuous learning, sustainability, and responsibility are at the core of our approach.

The people extending human lifespan